This paper aimed to systematically examine the efficacy and adverse occasion (AE) profile of cannabidiol and medicinal cannabis by analyzing qualitative and meta-analytic information. We utilised the terms (« Cannabidiol » OR « Cannabis ») AND « Epilepsy » AND (« Treatment » OR « Therapeutics ») as search phrases to retrieve research indexed on PubMed, ScienceDirect, and CENTRAL databases. The inclusion criteria had been as follows: clinical research with a longitudinal observational design and style and intervention utilizing cannabinoid derivatives, specifically cannabidiol and medicinal cannabis, whereby some final results involved the frequency of epileptic seizures. We utilised Cochrane Collaboration’s Overview Manager computer software (RevMan five.1.six) for the meta-evaluation and dichotomized the articles to a self-confidence interval of 95%. From 236 articles, we chosen 16 for descriptive evaluation we chosen only four for the meta-evaluation. According to the final results, a statistically meaningful impact of cannabidiol compared with placebo was observed (p < 0.00001). When comparing remedy with cannabidiol or medicinal cannabis, significance was not located for the AE profile (p = 0.74). As AEs for cannabidiol had been additional frequent beneath quick-term than beneath lengthy-term remedy (p < 0.00001), this method was favorable in the lengthy term. Moreover, cannabidiol is additional efficient than placebo, regardless of the etiology of epileptic syndromes and dosage. General, the AE profile did not differ across remedies with cannabidiol or medicinal cannabis, although it did differ favorably for lengthy-term than for quick-term remedy.
Copyright © 2019 Elsevier Inc. All rights reserved.